# Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

> **NCT01105741** · — · COMPLETED · sponsor: **Martin Storr** · enrollment: 25 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01105741
- **Lead sponsor:** Martin Storr
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105741, "Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01105741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*